Abstract
RNA interference consists of a sequence specific post-transcriptional gene silencing phenomenon triggered by a double strand RNA molecule homologous to the silenced gene. The dsRNA is cleaved by DICER enzyme in small dsRNA pieces, named short interfering RNAs (siRNAs). These fragments are thereafter associated to RISC complex where the cleavage of target RNA occurs. The observation that siRNAs can trigger the RNA interference mechanism in mammalian cells represents a fundamental discovery that discloses new horizons in genetic researches in that theoretically each gene can be silenced. The relative simplicity by which active short interfering RNAs can be designed and synthesized explains their widespread use in basic and applied researches, even if appropriate controls that exclude offtarget effects are strictly required. The findings that siRNAs are active even when expressed in viral vectors open the possibility that they can be very soon used for gene therapy of several human diseases.
Keywords: rna interference, short interfering rnas (sirnas), sirnas design, sirnas testing, gene expression knock down, expression vectors, functional genomics, therapeutics
Current Pharmaceutical Biotechnology
Title: RNA-Based Drugs: From RNA Interference to Short Interfering RNAs
Volume: 5 Issue: 4
Author(s): L. Poliseno, A. Mercatanti, L. Citti and G. Rainaldi
Affiliation:
Keywords: rna interference, short interfering rnas (sirnas), sirnas design, sirnas testing, gene expression knock down, expression vectors, functional genomics, therapeutics
Abstract: RNA interference consists of a sequence specific post-transcriptional gene silencing phenomenon triggered by a double strand RNA molecule homologous to the silenced gene. The dsRNA is cleaved by DICER enzyme in small dsRNA pieces, named short interfering RNAs (siRNAs). These fragments are thereafter associated to RISC complex where the cleavage of target RNA occurs. The observation that siRNAs can trigger the RNA interference mechanism in mammalian cells represents a fundamental discovery that discloses new horizons in genetic researches in that theoretically each gene can be silenced. The relative simplicity by which active short interfering RNAs can be designed and synthesized explains their widespread use in basic and applied researches, even if appropriate controls that exclude offtarget effects are strictly required. The findings that siRNAs are active even when expressed in viral vectors open the possibility that they can be very soon used for gene therapy of several human diseases.
Export Options
About this article
Cite this article as:
Poliseno L., Mercatanti A., Citti L. and Rainaldi G., RNA-Based Drugs: From RNA Interference to Short Interfering RNAs, Current Pharmaceutical Biotechnology 2004; 5 (4) . https://dx.doi.org/10.2174/1389201043376797
DOI https://dx.doi.org/10.2174/1389201043376797 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heme Oxygenase-Derived Carbon Monoxide Restores Vascular Function in Type 1 Diabetes
Drug Metabolism Letters Mouse Models of Myasthenia Gravis
Current Pharmaceutical Design Biologic Properties of Non-Antibiotic, Chemically Modified Tetracyclines (CMTs): A Structured, Annotated Bibliography
Current Medicinal Chemistry Genetic Variations and Subclinical Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus
Current Vascular Pharmacology Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design Intravenous Immunoglobulins for Alzheimer's Disease
Current Alzheimer Research Viral-Mediated Gene Transfer for Cancer Treatment
Current Pharmaceutical Biotechnology The Role of c-Myc in Beta Cell Mass Homeostasis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Antioxidant Activity of Plant Phenols: Chemical Mechanisms and Biological Significance
Current Organic Chemistry Apoptosis of Leukemia Cells by Ocimum basilicum Fractions Following TNF alpha Induced Activation of JNK and Caspase 3
Current Pharmaceutical Design Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechano-Regulation of Alternative Splicing
Current Genomics Prostaglandins and Cyclooxygenases in Glial Cells During Brain Inflammation
Current Drug Targets - Inflammation & Allergy The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy Angiogenesis Inhibition in the Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Contribution of Ultrasonography of Hands and Wrists in Early Rheumatoid Arthritis
Current Rheumatology Reviews Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Current Topics in Medicinal Chemistry